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Abstract Glioblastoma multiforme (GBM) remains
refractory to conventional therapy. CD133? GBM cells
have been recently isolated and characterized as chemo-/
radio-resistant tumor-initiating cells and are hypothesized
to be responsible for post-treatment recurrence. In order to
explore the molecular properties of tumorigenic CD133?
GBM cells that resist treatment, we isolated CD133?
GBM cells from tumors that are recurrent and have pre-
viously received chemo-/radio-therapy. We found that the
puriﬁed CD133? GBM cells sorted from the CD133?
GBM spheres express SOX2 and CD44 and are capable of
clonal self-renewal and dividing to produce fast-growing
CD133- progeny, which form the major cell population
within GBM spheres. Intracranial injection of puriﬁed
CD133?, not CD133- GBM daughter cells, can lead to
the development of YKL-40? inﬁltrating tumors that dis-
play hypervascularity and pseudopalisading necrosis-like
features in mouse brain. The molecular proﬁle of puriﬁed
CD133? GBM cells revealed characteristics of neuroec-
toderm-like cells, expressing both radial glial and neural
crest cell developmental genes, and portraying a slow-
growing, non-differentiated, polarized/migratory, astrogli-
ogenic, and chondrogenic phenotype. These data suggest
that at least a subset of treated and recurrent GBM tumors
may be seeded by CD133? GBM cells with neural and
mesenchymal properties. The data also imply that CD133?
GBM cells may be clinically indolent/quiescent prior to
undergoing proliferative cell division (PCD) to produce
CD133- GBM effector progeny. Identifying intrinsic and Electronic supplementary material The online version of this
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diminish the recurrence rate of GBM.
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Introduction
Glioblastoma multiforme (GBM, World Health Organiza-
tion/WHO grade IV) remains virtually incurable despite
extensive surgical excision and post-operative adjuvant
radio/chemotherapy. Currently, most anti-cancer therapies
aim to eliminate rapidly proliferating tumor cells; thus, the
novel discovery of rare and radioresistant CD133? GBM
stem cells possessing the enhanced ability to repopulate
tumors by multiple laboratories [1–5] provide a potential
model to explain the inability to eradicate malignant GBM
tumors. Tumor recurrence after treatment may mimic the
scenario of post-injury tissue repair and regeneration.
Many adult tissues undergo renewal after aging or injury,
and hence require a new supply of cells originating from
specialized tissue stem cells with the capability to undergo
self-renewal, asymmetric cell division, and multipotent
differentiation to repair aged cells or damaged tissue [6–9].
Stem cells often reside in stem cell niches that provide a
specialized environment to maintain and regulate their
properties and activity [10, 11]. The cellular hierarchy of
tissue regeneration by resident stem cells has been descri-
bed in the hematopoietic system, gut, and skin [12–14].
Tissue stem cells are most often slow-cycling and give rise
to daughter transient amplifying cells (TAC) that make up
the majority of the proliferative cell population in the tis-
sues, and eventually differentiate into non-proliferative
cells of a particular tissue type [15, 16]. The studies of
airway injury/repair in animal model indicated that airway
stem cells will only be induced to self-renewal when an
abundant number of TAC are depleted [17, 18], and the
elimination of the progenitor and stem cell pools has a
consequent failure of tissue regeneration [19]. Thus, at the
functional level, CD133? GBM stem cells behave in ways
that are similar to tissue stem cells; CD133? GBM stem
cells can self-renew and reconstitute the original tumor
tissue when grafted into mice [1–5]. Cancer stem cells
possess a multi-lineage differentiation capacity support for
the hypothesis that cancer hierarchy is a result of devel-
opmental diversity among cancer cells in different states of
differentiation [20–22]. However, it is plausible that mul-
tiple genetic and/or epigenetic instability that take place
within tumor stem cells might prevent progeny from
undergoing non-proliferative terminal differentiation,
leading to uncontrolled tumor growth [23–25].
Toaccessgenesandpathwayspotentiallyassociatedwith
malignant features of GBM tumors, we recently compared
the genome-wide transcription proﬁle of GBM tumors with
that of normal brain tissue and lower-grade astrocytoma
[26–28]. Besides those genes associated with inﬂammation,
coagulation,angiogenesis, and tissue remodeling, aseries of
genes linked with neural stem cell (NSC), mesenchymal
stem cells (MSC) and skeletal/cartilage development, was
determined. It thus implicates that a tissue regeneration-like
reaction is constitutively activated within GBM tumor situ.
The molecular proﬁles of tumor samples obviously do not
reﬂect those of the CD133? cancer stem cell population,
which only forms a small fraction of the whole tumor tissue
samples. In this study, we characterized CD133? GBM
stem cells puriﬁed from the passaged CD133? GBM sphere
cultures established from recurrent GBM tumors that had
previoustreatment.OurresultsindicatedthattheseCD133?
GBM cells have an unlimited ability to repopulate tumor
spheres in cultures and are capable of reconstituting a tumor
inmouse brainthat displays thekeyhistopathologic features
of malignant GBM tumor. Molecular proﬁle analysis
revealed CD133? GBM cells possess neuroectodermal-like
cell properties endowed with mesenchymal differentiation
and astrogliogenic potentials. Additionally, a list of over-
expressed genes characterized a quiescent-like state,
implying that CD133? GBM stem cells may be clinically
indolent prior to entering the proliferative phase of the cell
cycle to attain their malignant phenotype [29].
Materials and methods
Culture of primary GBM cells and tumor spheres
The tumor specimens were obtained from patients who
underwent surgery at University of California at Los
Angeles (UCLA) Medical Center. All samples were col-
lected under protocols approved by the UCLA Institutional
Review Board. The histopathologic typing and tumor
grading were done by one neuropathologist according to the
WHO criteria. Tumors were enzyme-digested and washed,
followed by red blood cell lysis of the pellet. Cells were
cultured in a serum-free NSC medium containing DMEM/
Ham’s F-12 (Mediatech, Manassas, VA) supplementedwith
20 ng/ml human recombinant epidermal growth factor
(EGF, Sigma-Aldrich, St. Louis, MO), 20 ng/ml basic
ﬁbroblast growth factor (FGF, Chemicon, Billerica, MA),
10 ng/ml leukemia inhibitory factor (LIF, Chemicon), and
19 B27 without vitamin A (Invitrogen, Carlsbad, CA). In
some cases, cells were cultured in DMEM/Ham’s F-12
supplemented with 5% fetal bovine serum for 1–2 passage
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viously reported [4]. The D431 spheres were derived from a
patient with primary/de novo GBM and S496 spheres were
derived from a patient with secondary/progressive GBM
[27]. Both tumors received radiation and chemotherapy
prior to their recurrence and re-operation. GBM sphere
cultures were split with acutase weekly (Sigma-Aldrich, St.
Louis, MO) and replaced with fresh media every other day.
Real-time quantitative (qt) and semi-qt reverse
transcriptase polymerase chain reaction (RT-PCR)
analysis
Real-time qtRT-PCR and semi-qtRT-PCR analysis were
performed to verify the expression of selected genes in
CD133? GBM cells and patient tumors. Samples were
subjected to total RNA extraction with RNeasy kit (QIA-
GEN, Valencia, CA) and reverse transcription by using a
Taqman RT Reagent Kit (Applied Biosystems, Foster City,
CA). Two microgram of puriﬁed total RNA was used as
template in RT and cDNA synthesis was done for 1 cycle at
50C for 30 min and 94C for 2 min. Real-time qtRT-PCR
was carried out with MJ Opticon PCR Analyzer (MJ
Research, Inc., Waltham, MA) using SYBR Green PCR
Core Reagents (Applied Biosystems). The reactions were
cycled 30 times [50C for 2 min and 95C for 10 min (94C
for 15 s, 58–60C for 1 min, and 72C for 1 min) 9 30
cycles]andtheﬂuorescencewasmeasuredattheendofeach
cycletoconstructampliﬁcationcurves.Amelting curvewas
done to verify the speciﬁcity of PCR products. Quantitation
of transcripts was calculated based on a titrated standard
curve co-run in the same experiment and calibrated with the
expression level of housekeeping gene (b-actin). The semi-
quantitative RT-PCR analysis was performed, using 5 ll
cDNA equivalents to 100 ng total RNA. The PCR reaction
cycles were carried out as described above. After ampliﬁ-
cation, PCR products (5 ll) were electrophoresed on 2%
agarose gel and visualized under ultraviolet light after
SYBR Green staining. Primer 3 Input (http://frodo.wi.mit.
edu/cgi-bin/primer3/primer3_www.cgi) was used to selec-
ted primers and nonredundant speciﬁc primer sequences
was veriﬁed using National Center for Biotechnology
Information BLAST (http://www.ncbi.nlm.nih.gov/blast/
Blast.cgi). The primer sequences and expected size of
ampliﬁedPCRproductsarelistedatsupplementaryTable 8.
Cell proliferation assay
The proliferative activity of pre-sorted and post-sorted
CD133? and CD133- GBM cells was determined by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS/PMS) colorimet-
ric assay (Promega, Madison, WI) according to the
manufacturer’s instructions. Cells were seeded into 96-well
tissue culture plates at a density of 10,000 cells per well in
triplicate in NSC selecting media and incubated for 24 h.
The optical density was measured at 490 nm after 4-h
incubation with MTS/PMS reagent.
Loss of heterozygosity analysis
Genomic DNA from sorted CD133? GBM cells was
ampliﬁed, labeled, and hybridized under the manufac-
turer’s recommended conditions using the GeneChip
Human Mapping 10 K Array XbaI 131 (Affymetrix, Santa
Clara, CA). Raw allele scores were processed using Af-
fymetrix GeneChip Chromosome Copy Number Tool 1.1
to estimate genome-wide chromosomal gains and losses.
Animal studies and preparation of parafﬁn slides
and frozen sections
Tumorigenicity of GBM cells was determined by injecting
the cells orthotopically. Six-week-old female or male
Beige/SCID mice were anesthetized and positioned into a
stereotactic frame. A burr hole was made using a Dremel
drill approximately 3 mm lateral and 1 mm posterior to the
intersection of the coronal and sagittal sutures (bregma).
Cells were injected using a Hamilton syringe at a depth of
3 mm in a volume of 2 ll. Animals were sacriﬁced when
any sign of neurological symptoms and morbidity/mori-
bundity was observed. Brain tissue were immediately
removed and ﬁxed in 10% formalin for 24 h and then
transferred to 70% ethanol. Mouse brains were embedded
in parafﬁn in an automatic tissue processor. Brains were
sectioned at 5-lm thickness and were mounted on micro-
scope slides. Brain tissue for frozen sections was placed in
O.C.T. embedding medium (Tissue-Tekm, Miles Inc.). The
sample tray was brieﬂy dipped in liquid nitrogen and was
sectioned at 5-lm thickness in a -20C cryostat and air-
dried. Slides were then stored at -70C until used for
hematoxylin and eosin (H–E) stain and immunohisto-
chemical analysis.
Immunocytochemical, histopathological,
and immunohistochemical analysis
The immunocytochemical analysis was performed on
GBM spheres seeded on an eight-chamber culture slide in
the presence of FGF/EGF/LIF for 48 h. Cells were washed,
ﬁxed in 4% paraformaldehyde and subjected to immuno-
ﬂuorescent staining. The following primary antibodies
were used: CD133 (1:100, Abcam, Cambridge, MA), nes-
tin (1:200, Chemicon, Temecula, CA), SOX2 (1:400; R&D
System, Minneapolis, MN), CD105 (3 lg/ml, R&D Sys-
tem), YKL-40 (1:50, Quidel, San Diego, CA) and collagen
J Neurooncol (2009) 94:1–19 3
123type I (1:50, Santa Cruz Biotech, Santa Cruz, CA). After
washing, cells were incubated with rhodamine red or Alexa
Fluor 488-conjugated goat anti-mouse IgG or goat anti
rabbit IgG (1:200, Invitrogen) and counterstained with
Hoechst 33342 (Invitrogen) to identify all nuclei. Histo-
pathological analyses were performed on frozen section or
parafﬁn slides stained with H–E staining as per standard
technique. Immunohistochemical staining was performed
on frozen-section slides. Slides were subject to a 1-h
blocking step followed by the application of primary
antibody or control antibody for 1 h at room temperature.
The following primary antibodies were used: CD31 (1:100,
Biocare Medical, Concord, CA), CD133, YKL-40 (1:100),
and SOX2 (1:100). The immunodetection was performed
using Vectastain ABC Standard kit and Vector NovaRED
(Vector Laboratories, Burlingame, CA).
Fluorescence-activated cell sorting analyses
and puriﬁcation of CD133? GBM cells
Fluorescence-activated cell sorting analyses (FACS) anal-
yses were employed to determine the percentage of cells
expressing stem cell markers. Dissociated cells were
stained with the following antibodies for 30 min at 4C:
anti-CD133-APC (Miltenyi Biotech, Auburn, CA), anti-
CD44-FITC (Caltag Laboratories, Burlingame, CA), anti
SOX2 (indirect staining, using Alexa Fluor 488-conjugated
goat anti-mouse IgG) and ﬂuorescence-conjugated isotype
IgG controls. 10,000 events were collected in each analy-
sis. The analyses were performed on a FACSCalibur ﬂow
cytometer (Becton Dickinson, San Jose, CA) and C10,000
events were collected in each analysis. To purify CD133?
GBM cells, dissociated cells were immunostained with
anti-CD133-APC under the sterile condition. The CD133?
and CD133- cells were sorted and collected on a BD
FACSAria
TM II cell sorter at 70 psi using a 70-lm nozzle.
The purity of post-sorted cells was determined.
Microarray procedures and data analysis
Molecular proﬁling and analysis were performed as
described [27]. Brieﬂy, cDNA was generated and con-
verted to cRNA probes using standard Affymetrix proto-
cols and hybridized to Affymetrix GeneChip U133 Plus 2.0
Array. The chips were scanned using the GeneArray
scanner (Affymetrix). The CEL ﬁles generated by the Af-
fymetrix Microarray Suite version 5.0 were converted into
DCP ﬁles using the DNA-Chip Analyzer (dChip 1.3;
http://biosun1.harvard.edu/complab/dchip/). The DCP ﬁles
were globally normalized, and gene expression values were
generated using the dChip implementation of perfect-
match minus mismatch model-based expression index. To
avoid inclusion of low-level and unreliable signals, the
higher signal needed to exceed 100 and be called present
by MAS 5.0 in[30% of the samples. All group compari-
sons were performed in dChip.
Gene annotation
Functional annotation of individual gene was obtained
from NCBI/Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/
entrez), the published literature in PubMed Central (NCBI/
PubMed), Online Mendelian Inheritance in Man (NCBI/
OMIM), Source database (http://source.stanford.edu/cgi-bin/
source/sourceSearch), Protein knowledgebase (UniProtKB)
(http://beta.uniprot.org/), and Information Hyperlinked over
Proteins (http://www.ihop-net.org/UniPub/iHOP/). Func-
tional categorization of expression-based clusters based on
gene ontology (GO) was performed using a web tool dChip
v1.3 software (http://www.hsph.harvard.edu/*cli/complab/
dchip/). After the hierarchical clustering was performed on
genes, dChip searches all branches with at least four func-
tionally annotated genes to assess whether a local cluster is
enriched by genes having a particular function with GO
term.
Results
GBM spheres contain a minor population of CD133?
cells and express neural and mesenchymal stem cell-
associated markers
Five GBM sphere cultures were initiated under NSC-
selective culture conditions; two of them (D431 and S496)
were expandable, and were used for current study. GBM
spheres were dissociated, clonally replated to prevent cells
from forming aggregates (4 9 10
4 cells/7 ml/10 cm dish),
and passaged weekly. Most notably, individual cells dis-
sociated from spheres showed distinct proliferative poten-
tials; some form abortive colonies, whereas others form
larger colonies varying in size (Fig. 1A), suggesting that
cells which formed spheres, are heterogeneous. When
compared to autologous GBM cell cultures growing in
serum-containing media, a more differentiated state, in
which a negligible percent of cells express CD133
(\0.5%), 7–10% CD133? GBM cells could be detected in
GBM sphere cultures, using FACS analysis (Fig. 1B).
Moreover, sphere formation analysis by limiting dilution
assay revealed 7–15% clonogenic efﬁciency (Fig. 1C),
indicating that the majority of cells within spheres are not
sphere-reinitiating cells. We then test whether these
bulk CD133? GBM spheres that contain majority of
CD133- GBM cells express GBM tumor-associated
genes that are linked with NSC and MSC and their cell
lineages as identiﬁed in GBM tumors [26–28]. Indeed,
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associated markers, including SRY (sex-determining
region Y)-box 2 (SOX2), nestin, YKL-40, collagen Type I,
and CD105 (endoglin) were determined (Fig. 1D). RT-
PCR analysis was used to conﬁrm the expression of addi-
tional GBM markers, including maternal embryonic leu-
cine zipper kinase (MELK), platelet-derived growth factor
receptor-alpha (PDGFR-a), SOX4, and musashi homolog 1
(MSI1) (data not shown), demonstrating that cultured
CD133? GBM spheres express molecular markers of
stem-like GBM tumors.
CD133? GBM spheres were generated and maintained
by CD133? GBM cells through self-renewal
and proliferative cell division
To determine whether CD133? GBM cells are sphere-re-
initiating cells, and responsible for generating CD133-
GBM progeny within spheres, CD133? GBM cells were
sorted from dissociated CD133? sphere cultures using
speciﬁc CD133 antibody and FACS analysis (Fig. 2A).
The purity of post sorted CD133? cells ranged from 92%
to 97%. Puriﬁed CD133? cells were seeded in 96-well
plates at the clonal density by limiting dilution. Notably,
daughter cells divided from a single CD133? GBM cell
grow rapidly and gradually pile up to form GBM spheres.
Moreover, populated cells are morphologically heteroge-
neous revealed by differences in cell size and the formed
spheres showed variation in shape (Fig. 2B) [30]. These
proliferative dividing cells are mostly CD133- cells as
evident by the determination of *90% CD133- GBM
cells in the expanded spheres (Fig. 2C). Meanwhile,
*10% CD133? GBM cells were determined in single
cell-initiated spheres, indicating CD133? GBM cells could
clonally self-renew, but apparently be maintained in a
slow-dividing status distinct from CD133- progeny. RT-
PCR analysis also provided evidence for the presence of
proliferative CD133- daughter cells within the growing
spheres, which showed a decreased level of CD133 tran-
scripts compared to that of puriﬁed CD133? GBM cells
(Fig. 2D). These data thus demonstrate that CD133? GBM
cells are capable of clonal self-renewal and giving rise to
fast-growing CD133- daughter cells.
To test whether CD133? cells are responsible for the
continuous propagation of GBM sphere in cultures, we
compared the growth expansion of puriﬁed CD133? cell-
initiated cultures with that of cultures initiated by the
puriﬁed CD133- progeny (Fig. 2E). In order to ensure that
CD133? cells were completely removed from the
CD133- fraction, post-sorted CD133- cells were
Fig. 1 CD133? glioblastoma (GBM) sphere culture derived from
treated and recurrence GBM tumors express neural and mesenchymal
stem cell-associated genes. A Under neural stem cell (NSC)-selective
conditions, passaged and dissociated GBM spheres can generate
single cells, small spheres, and large spheres ([50 cells), indicating
tumor spheres consist of progeny with different proliferative poten-
tials. Scale bar = 50 lm. B Propagated GBM sphere cultures contain
*7% to 10% of the CD133? GBM cells determined by ﬂow
cytometry analysis. C The clonogenic efﬁciency of dissociated
CD133? GBM spheres assayed by the limiting dilutions relatively
correlates to the % of the CD133? cells determined in the GBM
spheres. D CD133? GBM spheres express neural and mesenchymal/
chondrogenic-associated genes as indicated, determined by immuno-
cytochemical analysis. Scale bar = 25 or 50 lm, as indicated
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123subjected to a second round of cell sorting. The puriﬁed
CD133? and CD133- daughter cells sorted from the same
CD133? GBM sphere cultures initiated by the CD133?
GBM cells were respectively seeded in triplicate in 6-well
plates at the cell density of 10
4 cells/2 ml/well. Cell
counting was performed biweekly. Most notably, the
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GBM spheres for indeﬁnite passages
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123growth initiation of cell cultures seeded by puriﬁed
CD133? GBM cells (40–50 9 10
4 cells/ml in ﬁrst cell
counting) was delayed compared to that of puriﬁed
CD133- GBM cell-seeded culture (70–80 9 10
4 cells/
ml), which showed an enhanced growth rate in the early
passages (Fig. 2E, a). This determination was veriﬁed by a
short-term (24 h) proliferation assay on day 2 after sorting,
which also indicated a slower growth rate of freshly puri-
ﬁed CD133? GBM daughter cells compared to CD133-
GBM daughter cells sorted from the same sphere cultures
(Fig. 2E, b). We however, observed a lesser difference in
proliferative activity between CD133? S496- and
CD133- S496 cell-seeded cultures compared to the growth
differences between CD133? and CD133- D431 cell-seed
cultures. This may be due to puriﬁed CD133? S496 GBM
cell culture being able to drop from C95% purity to 5–10%
within *3 to 5 days, whereas it will take *2 weeks to
drop to *10% to 15% in D431 cells (data not shown).
Nevertheless, the pre-sorted GBM cells from the dissoci-
ated CD133? GBM spheres showed a better proliferative
activity than sorted CD133? or CD133- cells in either
cases (Fig. 2E, b). The growth of CD133- GBM cell-ini-
tiated cultures gradually dropped after repeated passaging
in contrast to that of CD133? cell-initiating cultures,
which showed a stable expansion (Fig. 2E, a, c). These
results thus indicate that CD133? GBM cells have the
capacity for unlimited self-renewal, which is required for a
long-term propagation of D431 and S496 GBM spheres in
cultures.
Cells spontaneously migrate out of GBM spheres
and form the surrounding monolayer
It was reported that neural precursor cells migrating out of
neurospheres in cultures and outgrowing into a monolayer
[31, 32]. We have also observed a similar in vitro character-
istic in GBM sphere cultures. GBM cells can spontaneously
migrateradiallyoutwardfromthesemi-adherentandﬂattened
GBM sphere bodies, resulting in a rim of monolayer cells
surrounding the spheres (Fig. 3A, a–e). Eventually, these
migrating cells outgrow into an adherent monolayer that
spread out over the surface of the culture dish (Fig. 3A, f).
Unexpectedly, these cultures contain a higher percentage of
CD133? GBM cells (15–30% for S496 and 50–70% for
D431) than non-adherent sphere cultures (Fig. 3B, a, b). The
majorityofCD133?GBMcellsco-expressSOX2andCD44
(Fig. 3B,c,d)asthose ofCD133- progeny insame cultures,
indicating that CD133? GBM cells sharing some of their
surface markers with their immediate progeny grew in the
samecultures.Sincenoadditionalfactorswereaddedintothe
culturetoinﬂuencethebehaviorofcells,suchacellmigration
maybeanintrinsicpropertythatreﬂectsinherentlymigratory
properties of the GBM tumor of origin, which may confer a
inﬁltrativenatureofGBMtumorsinbrainthatischaracterized
bytheabilitytomigrateandinvadetheadjacenthealthybrain
tissue. When these adherent cells were dissociated and
replated at clonal density, they can regrow as sphere cultures
(Fig. 3B, e) containing *10% CD133? cells (Fig. 3B, f).
CD133? GBM cells exhibit genomic abnormalities
and are capable of repopulating malignant GBM tumor
in mouse brain
Both CD133? D431 GBM cells and CD133? S496 GBM
cells exhibited loss of heterozygosity (LOH) at various
chromosome locations as determined using a high-density
single nucleotide polymorphism array analysis. Particu-
larly, LOH at chromosome 10 was found in both CD133?
GBM cells, whereas only CD133? S496 GBM cells
exhibited LOH in chromosome 17 (Fig. 3C). Additionally,
chromosome 7 was found to be ampliﬁed in CD133?
D431 GBM cells, and to a lesser degree in S496 cells.
Similar results were found in the autologous cell line
cultures passaging in the serum-containing media [28]. To
compare the in vivo fate of CD133? GBM cells and
CD133- GBM cells, cells were stereotactically injected
into the brains of SCID mice. Mice that received puriﬁed
CD133? GBM cells (5–10 9 10
3/2 ll) (11/12) sorted
from the CD133? GBM sphere cultures (6 mice per cell
type) showed impaired mobility at week 15–28 post-
injection, whereas mice that received CD133- GBM cells
(5 9 10
5/2 ll) (0/20) (10 mice per cell type) remained
normal at week 30. The injected CD133- GBM cells
include CD133- GBM cells sorted from the same
CD133? GBM sphere cultures that were used for sorting
CD133? GBM cells (post two rounds of cell sorting) (0/6),
the CD133- cells sorted from autologous GBM cell line
cultured in serum (0/6) (note, serum-cultured GBM cells
contain 0.2–0.35% CD133? cells) and serum-cultured
GBM cells switched to NSC culture media for 48 h (0/4)
and 6 days (0/4). The H–E staining of tumors demon-
strated hypercellular zones surrounding necrotic foci that
form the histopathologic features of pseudopalisading
necrosis as seen in human glioblastoma (Fig. 3D). Nota-
bly, S496 tumors (Fig. 3D, a–e) exhibited more enhanced
necrosis than that of D431 tumors (Fig. 3D, f–i). Immu-
nohistochemical staining revealed hypervascularity evi-
denced by the strong expression of CD31/platelet
endothelial cell adhesion molecule-1 (PECAM-1)
(Fig. 3D, k, l). The CD133 immunoreactive cells were
occasionally found (Fig. 3D, m, n), suggesting the
CD133- GBM daughter cells play the key role in pro-
moting the malignant features of tumor in mice. The
expression of nestin, SOX2, and YKL-40 in inﬁltrating
tumor cells (Fig. 3D, o–q) veriﬁed the GBM origin and
tumorigenic potential of CD133? GBM cells.
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123Shared CD133? GBM cell-associated genes revealed
neuroectodermal properties and a quiescent/
antiproliferative phenotype
To explore molecular properties of CD133? GBM cells,
we performed large-scale gene expression analysis using
DNA microarrays. Based on the in vitro characterization, it
is anticipated that CD133? and CD133- daughter cells
sorted from the same CD133? sphere cultures initiated by
CD133? GBM cells will share certain properties (e.g.
CD44, nestin, SOX2). Therefore, to assess genes that
characterized the tumorigenic, stem-like CD133? GBM
Fig. 3 CD133? GBM cells can reconstitute an inﬁltrating GBM
tumor in mouse brain that displays hypervascularity and pseudopal-
isading necrosis-like features. A Passaged CD133? GBM spheres
([20 passage) can radially migrate out of spheres extensively (a–f).
Magniﬁcation, 409 (f), 1009 (e), 2009 (a, d), 4009 (b, c). B The
ﬂow cytometry analysis indicated that the adherent GBM sphere
cultures contain a higher percentage of CD133? cells (20–70%) that
coexpressed SOX2 and CD44 (a–d). Replating adherent CD133?
GBM sphere culture cells at clonal cell density can re-initiate spheres
that contain *10% CD133? GBM cells (e, f). C Genomic
abnormalities that are associated with glioblastoma were detected in
CD133? GBM cells. CD133? GBM cells were evaluated for allelic
imbalances and chromosomal copy number abnormalities by using a
high-density single nucleotide polymorphism array analysis. X axis,
length of chromosomes 17, 10, and 7; Y axis, score of the evidence of
LOH or gain of gene copy. D Intracranial injection of puriﬁed
CD133?, not CD133- GBM daughter cells, can lead to the
development of inﬁltrating tumors. HE staining shows hypercellular
zones surrounding necrotic foci and the formation of a clear space
(a–i). The hypervascularity was displayed by the strong positivity of
CD31/PECAM-1 (platelet endothelial cell adhesion molecule-1) as
determined by immunostaining (k, l). CD133 immunoreactive cells
were occasionally found in small clusters (m, n). The expression of
nestin, SOX2, and YKL-40 in the inﬁltrating cells validates the origin
of human malignant GBM tumor (o–q). No immunoreactivity was
determined when the control antibody was applied (j). Magniﬁcation,
2009 (a–g; j–q), 4009 (h, i)
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123cells, we ﬁrst compared the mean level of normalized
expression proﬁles in each of the two puriﬁed CD133?
GBM cell samples (D431 and S496) (n = 3 preparations,
passage 20, 29, 40) against the non-tumorigenic, autolo-
gous CD133- GBM cells growing in serum (more differ-
entiated condition) with and without switching to a short-
term NSC culture condition (24 h, 48 h, and 6 days)
(n = 6 preparations). The short-term culture of cells in
NSC culture condition diminishes the likelihood of iden-
tifying NSC growth factor-responsive genes (background
genes) in the comparative analysis. Probe set signals on the
expression array that were C3-fold higher in each CD133?
GBM cell group versus the autologous CD133- GBM cell
group with a pairwise t-test (P\0.05) were selected. The
ﬁltering criteria were described in Materials and Methods.
Sixty-four shared genes overexpressed in CD133? GBM
cells were identiﬁed in both pairwise comparisons (D431
and S496), and CD133/prominin1 was highly differentially
expressed (D431 = 53 folds, S496 = 14 folds) as antici-
pated, which validates a good puriﬁcation process
(Table 1; Fig. 4A, a). The distinctive gene expression pro-
ﬁles ofselectedgenes were veriﬁedby real-time qt-RT-PCR
and semi-qt-RT-PCR (supplementary Fig. 1). The gene
function enrichment analysis identiﬁed 24 signiﬁcant GO
clusters (Fig. 4A), and 38% (ﬁnd 24 genes), 25% (ﬁnd 17
genes) and 25% (ﬁnd 17 genes) genes were found for GO
terms related to ‘‘development’’ (P = 0.000001), ‘‘system
development’’ (P = 0.000000) and ‘‘nervous system
development’’ (P = 0.000000)), respectively (supplemen-
tary Table 1). Indeed, a large percentage of genes are neu-
roectoderm-developmental genes (Table 1). Most notably,
Dlx5 and Dlx6 (see gene description in Table 1) are regu-
lators of chondrogenesis of limb [33] and are highly
expressed in cranial neural crest. MEOX2, MEST, and
FABP4characterizedmesenchymalprogenitors,andRARA
[34]andWnt antagonistFRZB [35] are likely tobeinducing
the signals to suppress the chondrocytic and skeletal pro-
genitor differentiation. Simultaneously, many genes reﬂec-
tive of the normal function of neural crest cells were
determined: SEMA6D for cardiac development, CHRNA9
forcochleahaircelldevelopment,PPEF1fordevelopmentof
cranial ganglion sensory neurons, and SHROOM2 for mel-
anosome biogenesis. Moreover, LGR5, a novel marker gene
foradultstemcellswasdetermined[36],indicatingCD133?
GBM cells share a property with other tissue stem cells.
Meanwhile, a series of genes functioning in antimitotic/
antigrowth effect was identiﬁed. For instance, MEOX2
suppresses cell proliferation in a p21-dependent manner
[37], SULF1 suppresses peptide growth factor signaling
and angiogenesis [38], IL17RD antagonizes FGF-induced
cell proliferation [39], and FRZB and VLDL act as nega-
tive regulators of the Wnt signaling pathway and angio-
genesis [40]. Simultaneously, EDN3, a potent mitogen for
early neural crest-derived glial and melanocytic precursors
[41], and GAP-43, a crucial component of an effective
neural regenerative response [42] were determined, impli-
cating a role for maintaining the basic growth activity of
CD133? GBM cells. Thus, the overall molecular proﬁle
characterizes CD133? GBM cells as having a slow-
growing, non-differentiated, self-renewing, chondrogenic,
and antidevelopmental phenotype.
Unique CD133? GBM cell-associated genes may
reﬂect inherently migratory properties of GBM tumor
of origin
The 50 most strongly differentially expressed genes only
over-expressed in each puriﬁed CD133? GBM cells sorted
from the CD133? GBM spheres were selected (supple-
mentary Tables 2 and 3). Uniquely, fatty acid binding
protein 7 (FABP7), a migratory radial glial cell (RGC)
gene, was identiﬁed as the top distinct gene in CD133?
S496. The FABP7 expressing RGC have been proposed to
be the malignant glioma cell of origin [43] and the
increased expression of nuclear FABP7 was found to be
associated with the regions of GBM tumor inﬁltration,
reduced survival, and recurrence [44]. On the other hand,
MYCN, a migratory neural crest cell gene, and MDM2, a
direct transcriptional target of MYCN, were detected in
CD133? D431. The overexpression of MDM2 is impli-
cated in the development of de novo GBM [45]. Additional
genes that are associated with cell migration machinery
expressed in either CD133? D431, CD133? S496 or both,
include genes that are associated with cell polarity (e.g.
GPC3, FZD1, EPH receptor B1/B3), motor protein
(KIF5C), assembly of microtubules and formation of
lamellipodia and ﬁlopodia (MAP2, RHOJ, RHOU, TNIK)
and formation of actin stress ﬁbers and focal adhesions
(SORBS1), pointing to an active migration characteristic of
CD133? GBM cells. More importantly, the determination
of Notch effector genes (HEY1, NFIA, ID4, FABP7)
reﬂected the prolonged Notch activation and abrogation of
neurogenesis, thereby promoting a migratory phenotype
and glial-fate speciﬁcation [46–50]. In general, both unique
gene lists are consistent with ‘‘anti-proliferative pheno-
type’’ as those of shared genes in Table 1.
CD133- GBM daughter cells divided from CD133?
GBM cells express molecular proﬁles associated
with malignant GBM phenotype
Since CD133? GBM cells sorted from CD133? GBM
spheres cultures expressed molecular proﬁles that charac-
terized a quiescent phenotype, it is reasonable to predict that
the malignant tumor-associated genes are mainly expressed
in CD133- GBM daughter cells, which make up the major
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123Table 1 Shared genes overexpressed in CD133? D431 and CD133? S496 GBM cells compared with autologous CD133- GBM cells cultured
in serum-containing media
Gene Symbol Gene I.D. Fold change Chromosome Functional involvement
D431 S496
Sema, transmembrane, and
cytoplasmic domain, 6D
SEMA6D 80031 117.89 4.16 15q21 Guidance of myocardial patterning in cardiac
development
Growth associated protein 43 GAP43 2596 110.32 25.56 3q13.1-q13.2 Nervous system regeneration
Distal-less homeo box 6 DLX6 1750 78.94 40.90 7q22 Craniofacial morphogenesis/chondrogenesis
BH-protocadherin (brain–heart) PCDH7 5099 62.58 3.76 4p15 Calcium-dependent cell–cell adhesion
Prominin 1/CD133 PROM1 8842 52.87 13.70 4p15.32 Neuroepithelial stem cell marker; cell
polarity
Endothelin 3 EDN3 1908 43.96 26.35 20q13.2-q13.3 Promotes neural crest cell and precursor
proliferation
ST8 alpha-N-acetyl-neuraminide
alpha-2,8-sialyltransferase 4
ST8SIA4 7903 43.56 5.39 5q21 Synthesis of polysialic acid in neural stem
cells
Transcription factor AP-2 beta TFAP2B 7021 37.28 23.09 6p12 Neural crest cell growth and differentiation
Distal-less homeo box 5 DLX5 1749 36.64 17.18 7q22 Craniofacial morphogenesis/chondrogenesis
Neurexin 3 NRXN3 9369 27.84 5.79 14q31 Stabilizes synapses
Cholinergic receptor, nicotinic,
alpha polypeptide 9
CHRNA9 55584 27.24 3.99 4p14 Cochlea hair cell development
Fatty acid binding protein 4,
adipocyte
FABP4 2167 26.43 70.07 8q21 Lipid and glucose metabolism
Peptidase inhibitor 15 PI15 51050 24.09 7.79 8q21.11 Expressed in neuroblastoma/glioblastoma
Cholinergic receptor, nicotinic,
alpha polypeptide 1 (muscle)
CHRNA1 1134 23.12 6.33 2q24-q32 Neuromuscular transmission
Glycoprotein M6B GPM6B 2824 23.12 5.79 Xp22.2 Stabilizes proteolipids in neuron
Sortilin-related VPS10 domain
containing receptor 1
SORCS1 114815 19.39 45.42 10q23-q25 Brain neuropeptide receptors
Protein phosphatase, EF-hand
calcium binding domain 1
PPEF1 5475 19.18 6.57 Xp22.2-p22.1 Speciﬁc sensory neuron function and/or
developments
Kinesin family member 5C KIF5C 3800 19.03 17.36 2q23.1 Neuronal kinesin enriched in motor neurons
Down syndrome critical region
gene 1-like 1
RCAN2 10231 18.71 10.06 6p12.3 Suppresses angiogenesis
Leucine-rich repeat-containing G
protein-coupled receptor 5
LGR5 8549 18.56 4.59 12q22-q23 Stem cell marker of small intestine, colon,
skin, hair
Glutamate receptor, ionotropic,
AMPA 1
GRIA1 2890 16.48 14.20 5q31.1 Excitatory neurotransmitter receptors
Mesenchyme homeo box 2 MEOX2 4223 15.64 47.53 7p22.1-p21.3 Somitogenesis; myogenic/sclerotomal
differentiation
Monooxygenase, DBH-like 1 MOXD1 26002 15.53 23.19 6q23.1-q23.3 Dopamine-oxygenase; neural crest/ganglia
marker
Cholinergic receptor, muscarinic 3 CHRM3 1131 14.44 7.26 1q43 Smooth muscle contraction; secretion of
glands
Sulfatase 1 SULF1 23213 13.96 30.43 8q13.2-q13.3 Remove 6-O-sulfate groups of heparan
sulfate
Regulator of G-protein signaling 5 RGS5 8490 13.19 15.10 1q23.1 Marker for pericytes; antiangiogenesis
Frizzled-related protein FRZB 2487 12.98 6.01 2qter Antagonizes Wnt pathway
Neurocalcin delta NCALD 83988 11.78 3.54 8q22.2 Neuronal calcium sensors; interact with S100
beta
Gamma-aminobutyric acid
(GABA) receptor, rho 1
GABRR1 2569 11.35 5.08 6q13-q16.3 Reduces sensitivity to retinoic acid
Protocadherin 19 PCDH19 57526 11.04 5.16 Xq13.3 Expressed in neuroepithelium
SRY (sex determining region Y)-
box 2
SOX2 6657 10.74 7.49 3q26.3-q27 Neural stem cell marker, self-renewal
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123Table 1 continued
Gene Symbol Gene I.D. Fold change Chromosome Functional involvement
D431 S496
TRAF2 and NCK interacting
kinase
TNIK 23043 9.72 3.41 3q26.2-q26.31 Regulates actin cytoskeleton
Mesoderm speciﬁc transcript
homolog (mouse)
MEST 4232 8.79 45.13 7q32 Expressed in mesodermal derivatives
Phosphorylase kinase, gamma 2
(testis)
PHKG2 5261 8.79 8.01 16p12.1-p11.2 Activates glycogen phosphorylase
Spondin 1, extracellular matrix
protein
SPON1 10418 8.43 33.87 11p15.2 Cementoblastic differentiation; inhibits
angiogenesis
Rap guanine nucleotide exchange
factor (GEF) 5
RAPGEF5 9771 8.42 19.43 7p15.3See RAS activator via maintain the GTP-bound
state
Trinucleotide repeat containing 9 TOX3 27324 8.36 56.65 16q12.1 Regulation of neurodevelopment or
neuroplasticity
Insulin-like growth factor binding
protein 2, 36 kDa
IGFBP2 3485 7.83 3.09 2q33-q34 Activation of the Akt and/K-Ras
Death-associated protein kinase 1 DAPK1 1612 7.69 15.44 9q34.1 Tumor suppressor
Formin homology 2 domain
containing 3
FHOD3 80206 7.49 3.15 18q12 Present in nestin-expressing neuroepithelial
cells
Scrapie responsive protein 1 SCRG1 11341 7.09 80.65 4q31-q32 Mesenchymal chondrogenesis, growth
suppression
Potassium large conductance
calcium-activated channel
KCNMB4 27345 7.09 6.00 12q Smooth muscle tone and neuronal excitability
Retinoic acid receptor, alpha RARA 5914 6.67 12.21 17q21 Marker for prechondrogenic progenitors
Neuroﬁlament, light polypeptide
68 kDa
NEFL 4747 6.6 6.28 8p21 Controls electrical signals travel down the
axon
Oxoglutarate (alpha-ketoglutarate)
dehydrogenase
OGDH 4967 6.24 4.36 7p14-p13 Krebs cycle
ADAM metallopeptidase
domain 23
ADAM23 8745 5.32 4.38 2q33 Tumor suppressor
Cadherin 2, type 1, N-cadherin
(neuronal)
CDH2 1000 5.06 11.21 18q11.2 Cell–cell adhesion; left-right asymmetry; cell
migration
Immunoglobulin superfamily,
member 4C
IGSF4C 199731 4.75 10.07 19q13.31 Tumor suppressor
Ankyrin 3, node of Ranvier
(ankyrin G)
ANK3 288 4.71 4.19 10q21 Maintenance of ion channels at nervous
systems
Alpha-2-macroglobulin A2M 2 4.31 11.49 12p13.3-p12.3 Protease inhibitor and cytokine transporter
Inhibin, beta A (activin A, activin
AB alpha polypeptide)
INHBA 3624 4.28 7.16 7p15-p13 Tooth development; tumor suppressor
Neuropilin 2 NRP2 8828 4.26 5.98 2q33.3 Axon guidance in the peripheral and central
neural system
Very low density lipoprotein
receptor
VLDLR 7436 4.18 5.83 9p24 Wnt antagonist; metabolism of apoprotein-E
Sortilin-related VPS10 domain
containing receptor 2
SORCS2 57537 3.81 8.95 4p16.1 Brain neuropeptide receptor
GalNAc-T10 GALNT10 55568 3.67 4.30 5q33.2 Predominant expression in CNS
FXYD domain containing ion
transport regulator 6
FXYD6 53826 3.49 22.75 11q23.3 Modulator of the Na, K-ATPase
Leucine rich repeat neuronal 3 LRRN3 54674 3.49 3.49 7q31.1 Developing ganglia and motor neurons
Interleukin 17 receptor D IL17RD 54756 3.44 9.59 3p14.3 Tumor suppressor-like role via FGF signaling
Pleiotrophin PTN 5764 3.37 4.86 7q33-q34 Heparin binding; neurite growth-promoting
factor
J Neurooncol (2009) 94:1–19 11
123population of CD133? GBM spheres and tumors. Indeed,
comparative analysis of puriﬁed CD133? and CD133-
GBM daughter cells sorted from the same CD133? GBM
sphere cultures that were initiated by the puriﬁed CD133?
GBM cells revealed a transition from a tumor suppressive-
likeproﬁletotumorigenicproﬁlewhenCD133?GBMcells
dividedandproducedCD133-GBMdaughtercells.Thetop
15 genes in molecular changes were presented (Table 2;
Fig. 4A,bandc),andtheCD133appearstobethetopdown-
regulated gene in both pairwise comparisons. Uniquely, the
gene function category analysis of gene changes in D431
cells identiﬁed 5 signiﬁcant clusters all belong to extracel-
lular component-associated GO terms (Fig. 4A, b), and 10
out of 30 genes (33%) under the GO term ‘‘extracellular
region’’
(P value = 0.000004) (supplementary Table 4). This
data thus suggests most genes that are modulated when
CD133?D431GBMcellsundergocelldivisionandproduce
fast-growing CD133- D431 daughter cells primarily
include genes associated with mesenchymal/extracellular
components. Evidently, two top genes, IBSP and YKL-40,
determined in CD133- daughter cells are markers of
osteoblast/chondrocyte differentiation and are angiogenic
factors. More importantly, YKL-40 is linked to the mesen-
chymal and recurrent GBM phenotype [51]. Several upreg-
ulated genes further point to the early onset of inﬂammatory
and angiogenic response. In contrast, genes that are down-
regulated in CD133- D431 daughter cells mostly are
CD133? D431 GBM associated genes (anti-proliferative
genes) as described (Table 1; supplementary Table 2).
Distinctively, most upregulated genes in sorted CD133-
S496 GBM daughter cells are associated with progression
of cell cycle (Table 2). The top gene, HMGCS1, is an
enzyme involved in the biosynthesis of lipid/cholesterol, a
critical component of biological membranes, and is thus
upregulated with constant cellular proliferation [52].
Several upregulated genes further point to the early onset
of proliferative differentiation, including CEBPZ, a
transcription factor for maintaining the cell differentiation
state, PIK3C2B, a downstream target of growth factor
receptors that link to the activation of the AKT pathway,
and PRKACB, a target gene of c-myc, which induces cell
transformation and tumor growth [53]. As expected, down-
regulated genes in sorted CD133- S496 GBM daughter
cells are mostly growth regulators and tumor suppressor
genes (Table 2). Indeed, 11 GO clusters that are mostly
related to membrane-associated components were deter-
mined (Fig. 4A, c), and 9 (30%) and 8 (27%) genes were
respectively found for GO term related to ‘‘protein com-
plex’’ (P value = 0.013675) and ‘‘plasma membrane’’
(P = 0.020780) (supplementary Table 5). This data thus
suggest when CD133? S496 GBM cells undergo cell
division and produce fast-growing CD133- S496 daughter
cells primarily through intrinsic cell-cycle-based mecha-
nism. The distinctive properties between D431 and S496
GBM cells also identiﬁed through the 2-way unsupervised
gene and sample clustering of non-sorted CD133? D431
and CD133? S496 GBM sphere cultures, which nicely
segregated two groups of samples (supplementary Fig. 2;
supplementary Table 6). YKL-40 was identiﬁed as the top
gene overexpressed in CD133? D431 GBM spheres (101-
fold increase) when compared to CD133? S496 GBM
spheres. By contrast, transmembrane protein 47, a gene that
expressed high level transcripts in brain, was identiﬁed as
the top gene overexpressed in CD133? S496 GBM sphere
cultures (233-fold increase). Correspondingly, gene func-
tion enrichment analysis showed distinct molecular path-
ways in the growth of two different CD133? GBM sphere
lines (mesenchymal developmental pathway versus neural
developmental pathway) (supplementary Fig. 2). Uniquely,
four gene clusters overexpressed in CD133? S496 spheres
were found for GO terms related to cell migration, cell
adhesion, cell motility, and locomotion (supplementary
Fig. 2), possibly explaining the enhanced inﬁltrating nature
of S496 tumor in mouse brain compared to that of D431
tumor (Fig. 3D).
Table 1 continued
Gene Symbol Gene I.D. Fold change Chromosome Functional involvement
D431 S496
Muscleblind-like 2 (Drosophila) MBNL2 10150 3.15 3.67 13q32.1 Skeletal muscle development
Microtubule-associated protein 2 MAP2 4133 3.09 4.36 2q34-q35 Microtubule assembly in neurogenesis
Apical protein-like (Xenopus
laevis)
SHROOM2 357 3.06 6.24 Xp22.3 Regulates melanosome biogenesis and
localization
EPH receptor B3 EPHB3 2049 3.01 8.71 3q21-qter Precise guidance of axon and neural crest cell
migration
FK506 binding protein 1B,
12.6 kDa
FKBP1B 2281 3.00 4.18 2p23.3 Excitation–contraction coupling in cardiac
muscle
Analysis was based on a cutoff of 3-fold increase in relative expression compared to autologous CD133- GBM cells (P\0.05). Individual P
value is shown in supplementary Table 7
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123Fig. 4 Analyses of gene expression proﬁles of puriﬁed, tumorigenic
CD133? GBM cells sorted from the CD133? GBM sphere cultures.
A All plots show normalized gene expression values converted into a
heat map. The log2 of the fold difference is indicated by the heat map
scale at the bottom. Each column is an individual sample organized
into cell types and culture conditions deﬁned at the top. Each row is a
single probe set measurement of transcript abundance for an
individual gene. The genes are listed in the same order from top to
bottom as the corresponding tables for each of the lists. (a) All genes
were ﬁltered to select transcripts with C3-fold expression in the
tumorigenic CD133? GBM cells (D431 and S496) sorted from the
CD133? sphere cultures (passage (p) 20, p29, and p40) compared
with the non-tumorigenic, autologous CD133- GBM cells cultured in
serum-containing media (p5, p10 and p15) with or without switching
to a short-term NSC culture condition for 24 h, 48 h and 6 days.
Sixty-four shared genes were identiﬁed from the intersection of the
comparisons between CD133? D431 GBM cells and CD133- D431
cells, and the comparison between CD133? S496 GBM cells and
CD133- S496 GBM cells. Functional categories of gene clusters
upregulated in the CD133? GBM cells were analyzed using a gene
ontology annotation–based gene function enrichment analysis (d-chip
software). (b, c) Gene changes in CD133- GBM daughter cells
compared to CD133? GBM daughter cells sorted from same
CD133? GBM sphere cultures. Genes that were upregulated or
down-regulated with C1.5-fold expression in CD133- GBM daugh-
ter cells compared with CD133? GBM daughter cells were collected.
The CD133? and CD133- GBM cells were sorted from the sphere
cultures at p20, p29, and p40. Functional categories of gene clusters in
GO terms were shown. B RT-PCR analysis showed that CD133?
GBM stem cell-associated transcripts are expressed in patient-derived
GBM tumors
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123Table 2 Top 15 gene changes in CD133- GBM daughter cells compared to CD133? GBM daughter cells sorted from the same CD133? GBM
sphere cultures
Gene Symbol Gene I.D. Fold change P value Functional involvement
A. Genes upregulated in CD133- D431 GBM daughter cells
Integrin-binding sialoprotein 3381 IBSP 10.13 0.01969 A major structural protein of the bone
matrices; angiogenesis
Chitinase 3-like 1
(cartilage glycoprotein-39)
1116 CHI3L1 6.93 0.039091 Chondrogenesis, glioblastoma
progression marker
Tryptophan 2,3-dioxygenase 6999 TDO2 5.62 0.00191 Enzyme involved in tryptophan
catabolism
Fibronectin 1 2335 FN1 4.61 0.039285 Binds to integrins/extracellular matrix;
promote tumor growth
Carbonic anhydrase XII 771 CA12 3.84 0.048487 Acidiﬁcation of the extracellular milieu; a
biomarker of gliomas
Hydroxysteroid (11-beta)
dehydrogenase 1
3290 HSD11B1 3.75 0.013701 Catalyzes the interconversion of inactive
cortisone to active cortisol
Solute carrier family 7 23428 SLC7A8 3.63 0.005935 Transport of neutral amino acids/essential
amino acids
Stonin 2 85439 STON2 3.55 0.020396 A component of the endocytic machinery;
regulates vesicle endocytosis
Plexin A4, A 57671 PLXNA4 3.48 0.039696 Mediates multiple semaphorin signals and
regulates axon guidance
Calcium/calmodulin-dependent
protein kinase II inhibitor 1
55450 CAMK2N1 3.42 0.011008 Inhibit brain CaM-kinase II activity
Anthrax toxin receptor 1 84168 ANTXR1 3.28 0.031259 Mediates cell spreading by coupling
extracellular ligands to the actin
Growth differentiation factor 15 9518 GDF15 3.06 0.004578 Tissue differentiation and maintenance
Matrix metallopeptidase 14
(membrane-inserted)
4323 MMP14 3.03 0.01905 Angiogenesis, tumor invasion
Elastin microﬁbril interfacer 1 11117 EMILIN1 3.02 0.029463 Extracellular matrix constituent
associated with elastic ﬁbers
Tissue factor pathway inhibitor 3675 TFPI 3.02 0.000305 Regulates the coagulation pathway;
dynamic conduction of blood
B. Genes downregulated in CD133- D431 GBM daughter cells
Prominin 1/CD133 8842 PROM1 -8.19 0.004998 Membrane protuberances and cell polarity
Glutamate receptor, ionotrophic,
AMPA 4
2893 GRIA4 -4.03 0.007852 Excitatory neurotransmitter receptors
v-Myc myelocytomatosis viral
related oncogene
4613 MYCN -3.91 0.006193 Embryonal tumor initiation factor
PRKC, apoptosis, WT1, regulator 5074 PAWR -3.64 0.001191 Tumor suppressor; apoptosis induction
Ksp37 protein 83888 KSP37 -3.46 0.016226 Protein produced by CD4 and cytotoxic
lymphocytes
Sidekick homolog 2 (chicken) 54549 SDK2 -3.43 0.011413 Cell adhesion protein that guides axonal
terminals
Frizzled-related protein 2487 FRZB -3.38 0.00987 Antagonizes Wnt pathway
Cytoplasmic FMR1 interacting
protein 2
26999 CYFIP2 -3.37 0.002989 A direct p53 target gene; cellular
apoptosis
Monooxygenase, DBH-like 1 26002 MOXD1 -3.31 0.006728 Predicted to hydroxylate a substrate in the
endoplasmic reticulum
Complement factor H 3075 CFH -3.13 0.011463 Inhibition of complement activation
Activated leukocyte cell adhesion
molecule
29995 ALCAM -3.08 0.002511 Marker of mesenchymal/colorectal cancer
stem cells; growth control
LIM and cysteine-rich domains 1 214 LMCD1 -3.08 0.007018 Represses GATA6 in the maintenance of
the differentiated phenotype
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Gene Symbol Gene I.D. Fold change P value Functional involvement
Scrapie responsive protein 1 11341 SCRG1 -2.98 0.010901 Mesenchymal chondrogenesis, growth
suppression
v-Myb myeloblastosis viral
oncogene homolog (avian)
4602 MYB -2.97 0.049344 Intrinsic factor for neural progenitor cell
proliferation
Cholinergic receptor, nicotinic,
alpha polypeptide 3
1136 CHRNA5 -2.97 0.016751 Ligand-binding subunit of the ganglionic
type nicotinic receptor
C. Genes upregulated in CD133- S496 GBM daughter cells
3-Hydroxy-3-methylglutaryl-
Coenzyme A synthase 1
3157 HMGCS1 3.09 0.020826 Cholesterologenesis
Solute carrier family 7 23428 SLC7A8 2.87 0.035311 Transport of neutral amino acids/essential
amino acids
Mitochondrial ribosomal protein
L30
51263 MRPL30 2.60 0.00943 Protein synthesis within the
mitochondrion
mRNA turnover 4 homolog 51154 MRTO4 2.56 0.007082 mRNA turnover and ribosome assembly
CCAAT/enhancer binding protein
zeta
10153 CEBPZ 2.31 0.010864 Maintains differentiated state; enhances
osteoblastic differentiation
v-Rel reticuloendotheliosis viral
oncogene homolog A
5970 RELA 2.25 0.007044 Cell survival, antiapoptosis
Endothelin 3 1908 EDN3 2.01 0.04014 Promotes neural crest cell and precursor
proliferation
Guanine nucleotide binding
protein-like 3 (nucleolar)-like
54552 GNL3L 1.89 0.022775 Processing of nucleolar preribosomal
RNA
Adaptor-related protein complex 1,
sigma 2 subunit
8905 AP1S2 1.89 0.03494 Protein sorting and assembly of endocytic
vesicles
Protein kinase, cAMP-dependent,
catalytic, beta
5567 PRKACB 1.62 0.04107 Proliferation and differentiation; c-myc
target gene; tumorigenesis
SLIT-ROBO Rho GTPase
activating protein 3
9901 SRGAP3 1.55 0.038237 Negatively regulates cell migration
Integrin, beta 8 3696 ITGB8 1.55 0.042396 Brain vascular morphogenesis in the
developing CNS
Monoamine oxidase A 4128 MAOA 1.53 0.034433 Degrades amine neurotransmitters
Phosphoinositide-3-kinase,
class 2, beta polypeptide
5287 PIK3C2B 1.53 0.034433 Proliferation, survival; intracellular
vesicle transport
Baculoviral IAP repeat-containing 4 331 XIAP 1.52 0.022379 Blocks the apoptosis pathway via
inhibiting caspase-3, 7, and 9
D. Genes downregulated in CD133- S496 GBM daughter cells
Prominin 1/CD133 8842 PROM1 -11.00 0.039802 Membrane protuberances and cell polarity
Phosphorylase kinase, gamma 2
(testis)
5261 PHKG2 -5.95 0.008141 Activates glycogen phosphorylase
BH-protocadherin (brain–heart) 5099 PCDH7 -2.86 0.013744 Calcium-dependent cell–cell adhesion
Inhibin, beta A (activin A, activin
AB alpha polypeptide)
3624 INHBA -2.82 0.026005 Tooth development; tumor suppressor
Melanoma cell adhesion molecule 4162 MCAM -2.81 0.013207 Putative adhesion molecule in neural crest
cells/melanoma
Low density lipoprotein-related
protein 1
4035 LRP1 -2.75 0.018718 Lipid metabolism; antigrowth, tumor
suppressor
Leucine rich repeat neuronal 6C 158038 LINGO2 -2.69 0.014473 Expressed in limbic system and neocortex
AF4/FMR2 family, member 3 3899 AFF3 -2.68 0.008324 Regulation of lymphoid development
Nephronectin 255743 NPNT -2.65 0.013665 Tumor suppressor
ADAM metallopeptidase with
thrombospondin type 1 motif 1
9510 ADAMTS1 -2.60 0.017533 Antiangiogenesis
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123Expression of CD133? GBM-associated transcripts in
patients’ GBM tumors
Several CD133? GBM-associated genes identiﬁed from
the current two CD133? GBM stem cell models have
never been reported as GBM tumor-associated genes. By
using RT-PCR analysis, a subset of selected CD133?
GBM-associated transcripts could be ampliﬁed in patient-
derived GBM tumors (n = 6 patients) (Fig. 4B), suggest-
ing the current culture strategy can preserve GBM stem cell
properties.
Discussion
Cancer stem cell model and hypothesis has greatly changed
the biological and clinical views of cancer [1–5, 54]. The
molecular proﬁles of puriﬁed CD133? GBM stem cells
derived from the previously treated recurrent tumors
characterized dormant-like cells and therefore support the
hypothesis that quiescent nature of CD133? GBM stem
cells may underline the treatment resistant to the conven-
tional therapy. The quiescent nature of cancer stem cells
has been described in chronic myeloid leukemia (CML),
where CML stem cells remain viable in a quiescent state
even in the presence of growth factors and tyrosine kinase
inhibitor [55, 56]. Indeed, while the genetic changes and
tumorigenic potential were demonstrated in puriﬁed
CD133? GBM cells sorted from the CD133? GBM
spheres, the molecular proﬁle characterized an antiprolif-
erative nature of CD133? GBM stem cells, suggesting the
pathologic effects of molecular changes to be manifested
primarily in a more differentiated progeny. Indeed, the
molecular proﬁles of CD133? GBM spheres (contain
majority of CD133- daughter cells) initiated by the puri-
ﬁed CD133? GBM cells express ‘‘proliferative tumor
markers’’ as that of CD133- GBM daughter cells, which
distinctive to the quiescent CD133? GBM daughter cells.
Thus, the more differentiated CD133- GBM progeny
should be considered as the true effector cells characterized
fast-growing and highly angiogenic GBM tumors. The
mechanisms and pathways underlying the spontaneous re-
entry into active cell cycle from the quiescent state in
cultures and in animal experiments remain to be elucidated
[57].Incontrasttothatfast-growingCD133-daughtercells,
the predicted slow-cycling, non-inﬂammatory, and non-
angiogenic nature of CD133? GBM cells (based on the
molecular proﬁles) may explain that GBM tumor can not be
eradicated by the anti-cell cycle-based radiochemotherapy,
anti-inﬂammatory drugs, or antiangiogenic agents.
A hallmark of all stem cells is the ability to simulta-
neously make identical copies of themselves (e.g. CD133?
GBM daughter cells) and give rise to a hierarchy of more
differentiated progeny (e.g. CD133- GBM daughter cells).
Indeed, CD133? GBM cells fulﬁll this deﬁnition and are
capable of undergoing cell division that give rise to a
malignant tumor tissue. GBM spheres initiated with one
single CD133? GBM cell contain heterogeneous popula-
tion that showed differences in cell size and proliferative
potential. By RT-PCR analysis, we were able to amplify
both Numb and Numb-like signals in CD133? GBM cells
(data not shown), suggesting CD133? GBM cells may
possess normal neuroepithelial-like properties capable of
undergoing asymmetric cell divisions, thereby maintaining
a tumor-suppressor-like phenotype [58]. Prominin/CD133
is selectively localized in protrusions of the apical mem-
brane in neuroepithelial cells, and it was suggested that
CD133 plays an important role in the maintenance of
apical-basal polarity [59]. Therefore, loss of CD133 (or
with other genes) may restrict CD133- GBM daughter
cells to the symmetric mode of cell division and act like
proliferative intermediate progenitor cells [60, 61].
Consequently, increasing the number of CD133? GBM
cells within the tumor would reﬂect a fast generation of
proliferative and angiogenic CD133- daughter cells to
form the bulk tumor [5, 62]. While our data indicated that
Table 2 continued
Gene Symbol Gene I.D. Fold change P value Functional involvement
Forkhead box C1 2296 FOXC1 -2.59 0.022414 Arrests cells in the G0/G1 phase; tumor
suppressor
AT rich interactive domain 1A (SWI-like) 8289 ARID1A -2.56 0.029044 Differentiation-associated cell cycle
arrest; tumor suppressor
Solute carrier family 4, anion exchanger,
member 2
6522 SLC4A2 -2.52 0.025985 Housekeeping regulator of intracellular
pH; tumor suppressor
La ribonucleoprotein domain family,
member 1
23367 LARP1 -2.51 0.01622 Protects the 30 end of nascent small RNAs
from exonuclease digestion
Collagen, type IV, alpha 2 1284 COL4A2 -2.42 0.008793 Inhibits angiogenesis and tumor growth
Analysis was based on a cutoff of 1.5-fold changes in relative expression compared to CD133? GBM daughter cells (P\0.05)
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123GBM tumor growth in these two study cases depends on
the CD133? GBM cells, GBM tumor growth seemed to
depend on CD133- GBM tumor-initiating cells for other
cases [63, 64]. The isolation of CD133? GBM cells from
CD133- GBM cell-initiating tumor was also reported [65],
indicating the CD133 is not an obligated marker for GBM
stem cells.
We previously showed that GBM tumor lines estab-
lished from recurrent tumors possess mesenchymal differ-
entiation potential [29]. A recent study further showed that
GBM stem cells formed tumors capable of undergoing
mesenchymal differentiation [64]. The expression of mes-
enchymal developmental genes in CD133? GBM stem
cells may therefore provide a potential explanation for the
chondrogenic/mesenchymal differentiation in tumors [66]
and the shifting toward the mesenchymal phenotype upon
tumor recurrence [49]. Moreover, based on the molecular
proﬁles of puriﬁed CD133? GBM cells, we hypothesize
that the cell-of-origin of GBM tumors may be the migra-
tory neural crest-like cell or radial glial-like cell. Overex-
pression of radial glial cell (RGC) marker, FABP7, in
CD133? GBM cells supports the recent ﬁnding that RGC
can give rise to adult subventricular zone stem cells [67].
On the other hand, although overexpression of MYCN is
associated with a childhood malignant tumor of neural
crest origin, it was recently found to be one of the most
frequently ampliﬁed oncogenes in GBM tumors (42%)
[68]. More samples should be analyzed in order to gener-
alize these observations. Moreover, whether these molec-
ular properties also applied in the general properties of
CD133? GBM cells derived from the non-treated tumor
remain to be investigated. Gene expression proﬁle analyses
of GBM tumors by DNA microarrays support the notion
that tumor development may indeed via distinct oncogenic
mechanisms among the GBM subtypes [26, 27, 69, 70].
The thought of heterogeneity in the pathway of GBM
tumor development is further supported by the recent
ﬁnding in studies of expression proﬁles of GBM sphere
cultures, which showed distinct molecular properties
among the GBM stem cell lines [51, 63, 64]. Likewise,
although CD133? GBM cells sorted from CD133? D431
and CD133? S496 spheres express shared molecular
properties, unsupervised gene and sample clustering seg-
regated two GBM sphere lines by the genes that are
associated with mesenchymal developmental pathway
versus neural developmental pathway, thus implying the
distinct cellular-origin of these two recurrent tumors.
In summary, we characterized CD133? GBM stem cells
isolated from two tumors that are recurrent and had pre-
vious treatment. Our in vitro and in vivo data suggest that
the tumorigenic CD133? GBM stem cells are maintained
at dormant-like stage state but are able to spontaneously
enter the proliferative cell cycle to generate highly
proliferative and angiogenic CD133- GBM daughter cells
(animal data). This observation implies that tumorigenesis
may be initiated through asymmetric cell division of
CD133? GBM cells [71, 72]. Thus, identifying the genes
and pathways that promote the CD133? GBM cells
entering proliferative cell division cycle may facilitate the
development and design of more effective therapies that
speciﬁcally target the tumorigenic potential of CD133?
GBM stem cells.
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